SCHEMBL4936610

SCHEMBL4936610

O=C(O)CC1CCC(c2ccc(-c3cc(OCc4ccc(C(F)(F)F)cc4)n[nH]3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 15/20 0.54
SOAT1 P35610 5/20 0.54
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
KCNH2 Q12809 2/20 0.42
PTPN2 P17706 2/20 0.40
PTPN1 P18031 2/20 0.40
PTPN6 P29350 2/20 0.40
FAAH O00519 1/20 0.39
CHRM2 P08172 1/20 0.39
DGAT2 Q96PD7 1/20 0.39
PDE10A Q9Y233 1/20 0.39
ADORA2A P29274 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487832 0.89 DGAT1 (0.45) DGAT1SOAT1FAAHCHRM2DGAT2
SCHEMBL4330968 0.84 PRMT5 (0.44) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL4941297 0.84 DGAT1 (0.42) DGAT1SOAT1FAAHCHRM2DGAT2
SCHEMBL4937153 0.83 DGAT1 (0.45) DGAT1SOAT1KCNH2FAAHCHRM2
SCHEMBL14813186 0.83 DGAT1 (0.45) DGAT1SOAT1KCNH2FAAHCHRM2
SCHEMBL4481941 0.82 DGAT1 (0.47) DGAT1SOAT1FAAHCHRM2DGAT2
SCHEMBL4939698 0.81 DGAT1 (0.43) DGAT1SOAT1FAAHCHRM2DGAT2
SCHEMBL14813110 0.80 DGAT1 (0.45) DGAT1SOAT1FAAHCHRM2DGAT2
SCHEMBL4463043 0.80 DGAT1 (0.45) DGAT1SOAT1FAAHCHRM2DGAT2
SCHEMBL4467174 0.80 DGAT1 (0.45) DGAT1SOAT1FAAHCHRM2DGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2117526-B1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LAB (US) 2013-04-03 EP claimed
US-20120238581-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2012-09-20 US claimed
US-20080182861-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2008-07-31 US claimed
US-8586594-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBVIE INC. (US) 2013-11-19 US disclosed
EP-2117526-B1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LAB (US) 2013-04-03 EP disclosed
US-20120238581-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2012-09-20 US disclosed
US-8202878-B2 Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid ABBOTT LABORATORIES (US) 2012-06-19 US disclosed
US-20080182861-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238581-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME DGAT1, DGAT2, LCAT DGAT1 1/4885SOAT1 4/4885RXRA 3298/4885
US-20080182861-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME DGAT1, DGAT2, LCAT DGAT1 1/4885SOAT1 4/4885RXRA 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.